Home
CAPR
CAPR News

Latest Capricor Therapeutics Inc. (CAPR) News on April 2, 2025

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

GlobeNewswire

12 hours ago

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.

5 days ago

High Growth Tech Stocks In The US Market With Promising Potential

Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

11 days ago

Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings

Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

12 days ago

Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations

Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey

12 days ago

Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?

Thomson Reuters StreetEvents

12 days ago

Q4 2024 Capricor Therapeutics Inc Earnings Call

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

13 days ago

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

13 days ago

Capricor Therapeutics Q4 Loss Widens, Revenue Decreases

Associated Press Finance

13 days ago

Capricor: Q4 Earnings Snapshot

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

13 days ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Simply Wall St.

14 days ago

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

TipRanks

14 days ago

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

MT Newswires

15 days ago

Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

15 days ago

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

GlobeNewswire

22 days ago

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

MT Newswires

22 days ago

Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

PR Newswire

23 days ago

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

GlobeNewswire

25 days ago

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Insider Monkey

a month ago

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Benzinga

a month ago

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

MT Newswires

a month ago

Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

GlobeNewswire

a month ago

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now?

Insider Monkey

a month ago

Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now?

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

a month ago

High Growth Tech Stocks In The United States To Watch

Capricor Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

2 months ago

Capricor Therapeutics to Participate in Upcoming Investor Conferences

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Zacks

2 months ago

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Simply Wall St.

2 months ago

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks

3 months ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

MT Newswires

3 months ago

Capricor Completes BLA Submission for Deramiocel to Treat DMD Cardiomyopathy

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

3 months ago

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In December 2024

Capricor Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

MT Newswires

4 months ago

Capricor Gets Orphan Drug, Advanced Therapy Medicinal Product Designations for Deramiocel in Europe

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

GlobeNewswire

4 months ago

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

MT Newswires

4 months ago

JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Insider Monkey

5 months ago

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

5 months ago

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Capricor Therapeutics Inc Earnings Call

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

Zacks

5 months ago

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

MT Newswires

5 months ago

Capricor Therapeutics Q3 Net Loss Widens, Revenue Declines From Year-Ago Levels

Associated Press Finance

5 months ago

Capricor: Q3 Earnings Snapshot

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

GlobeNewswire

5 months ago

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Zacks

5 months ago

Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Zacks

5 months ago

Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

5 months ago

Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

GlobeNewswire

5 months ago

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

5 months ago

High Growth Tech Stocks to Watch in October 2024

MT Newswires

5 months ago

Piper Sandler Initiates Capricor Therapeutics at Overweight With $35 Price Target

MT Newswires

5 months ago

Capricor Therapeutics Closes Underwritten Public Offering

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

5 months ago

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MT Newswires

6 months ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday

MT Newswires

6 months ago

Capricor Therapeutics Prices $75 Million Common Stock Offering

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

GlobeNewswire

6 months ago

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

MT Newswires

6 months ago

Capricor Therapeutics Starts Public Stock Offering

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

6 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor touts long-term efficacy of DMD therapy ahead of FDA application

Clinical Trials Arena

6 months ago

Capricor touts long-term efficacy of DMD therapy ahead of FDA application

Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years

Benzinga

6 months ago

Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years

MT Newswires

6 months ago

Capricor Reports Positive Data in Duchenne Muscular Dystrophy Study; Shares Rise

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

GlobeNewswire

6 months ago

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Capricor Therapeutics Inc (CAPR) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

6 months ago

Capricor Therapeutics Inc (CAPR) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

6 months ago

Capricor Therapeutics Submits Biologics License Application to FDA for Duchenne Muscular Dystrophy Drug Candidate

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

6 months ago

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?

Zacks

6 months ago

Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Capricor to Show Trial Data Over Long-Term Benefits of Deramiocel in DMD; Shares Soar

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

GlobeNewswire

6 months ago

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?

Insider Monkey

6 months ago

Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?

High Growth Tech Stocks To Watch In September 2024

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In September 2024

MT Newswires

6 months ago

Oppenheimer Adjusts Capricor Therapeutics Price Target to $43 From $15, Maintains Outperform Rating

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Cantor Fitzgerald Adjusts Capricor Therapeutics Price Target to $25 From $8, Maintains Overweight Rating; Shares Rise

MT Newswires

6 months ago

Capricor Therapeutics to Seek Full Approval of Deramiocel to Treat DMD Cardiomyopathy; Shares Rise

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

GlobeNewswire

6 months ago

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?

Zacks

6 months ago

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

GlobeNewswire

6 months ago

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

MT Newswires

6 months ago

Oppenheimer Adjusts Capricor Therapeutics Price Target to $15 From $14, Maintains Outperform Rating

MT Newswires

6 months ago

Capricor Therapeutics, Nippon Shinyaku Sign Binding Term Sheet for Commercialization of Duchenne Muscular Dystrophy Treatment in Europe

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

6 months ago

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm

Benzinga

7 months ago

EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

GlobeNewswire

7 months ago

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Things Look Grim For Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Today's Downgrade

Simply Wall St.

8 months ago

Things Look Grim For Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Today's Downgrade

Capricor Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Capricor Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

Zacks

8 months ago

Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

8 months ago

Capricor: Q2 Earnings Snapshot

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

GlobeNewswire

8 months ago

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

MT Newswires

9 months ago

Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

GlobeNewswire

9 months ago

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Capricor’s cell therapy shows three year benefit in DMD patients

Clinical Trials Arena

9 months ago

Capricor’s cell therapy shows three year benefit in DMD patients

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

GlobeNewswire

9 months ago

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

CORRECTION: Capricor Therapeutics

GlobeNewswire

9 months ago

CORRECTION: Capricor Therapeutics

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

9 months ago

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

MT Newswires

10 months ago

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires

10 months ago

Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

10 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

10 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

10 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Share on Social Networks: